Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 4Sarcoma 4Genitourinary 4Gastrointestinal 4CNS 4Other solid neoplasm 3Endocrine 3Dermatologic 3Breast 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2NET 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 2Multiple Myeloma 2

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × vatalanib × Plasma cell × Clear all
NCT00240162 2014-09-17

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

Washington University School of Medicine

Phase 2 Terminated
21 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00165347 2007-12-21

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
10 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡